P-0303 Safety and Tolerability data from A Phase II Study of Auy922 Compared with Chemotherapy in Patients with Advanced Gastric Cancer

Kun‐Huei Yeh(National Taiwan University Hospital), Zev A. Wainberg(University of California, Los Angeles), Scott Pain(Idorsia (Switzerland)), Mikhail Akimov(Novartis (Switzerland)), Jean‐Pierre Delord, Nimit Singhal(Royal Adelaide Hospital), Seok Yun Kang(Ajou University), Jen‐Shi Chen(Linkou Chang Gung Memorial Hospital), Sara De Dosso(Institute of Oncology Research), Yoon‐Koo Kang(Ulsan College), Alberto F. Sobrero(Ospedale Policlinico San Martino), Lisa Nardi(Novartis (United States))

Annals of Oncology

June 1, 2012

10.1016/s0923-7534(20)30237-4

Cited by 1

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

|The Lancet|2010|7.3k

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

|The Lancet|2018|1.7k

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

|NEJM Evidence|2022|1.4k

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

|The Lancet|2012|1.4k

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2023|1.1k